Investigation of the pathophysiology of progression in multiple sclerosis
Full text
Related documents
The third used immunomodulatory or immunosuppressive intervention (natalizumab, mitoxantrone or rituximab) and assessed MS patients pre- and 12-24 months post-treatment.
During the 400 patient years on low-dose treatment in this study, the frequency of disease break- through was low which indicates that treatment with a low- dose protocol (i.e.
associated with one-year natalizumab treatment in 31 MS patients regarding cytokine and chemokine levels in CSF and blood using multiplex bead assay analyses (paper I),
Natalizumab Treatment in Multiple Sclerosis Studies on lymphocytes, inflammatory markers and. magnetic
To investigate whether the expression profiles reflected disease activity, hierarchical clustering was performed on the gene expression profiles of peripheral T-cells from
Prolonged increase of NFL and granzyme A levels in CSF after a relapse support an ongoing immunological attack even after apparent clinical remission suggesting a dissociation
Aims: The aims of this thesis were to evaluate rituximab as a treatment alternative in relapsing remitting MS (RRMS) by describing the clinical effect and patient
Aims: The aims of this thesis were to evaluate rituximab as a treatment alternative in relapsing remitting MS (RRMS) by describing the clinical effect and patient related